OptimizeRx (NASDAQ:OPRX) Receives Buy Rating from Lake Street Capital

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reiterated by analysts at Lake Street Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $11.00 price objective on the stock. Lake Street Capital’s price target suggests a potential upside of 122.67% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. Stephens began coverage on shares of OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target on the stock. Roth Mkm restated a “buy” rating and set a $16.00 price objective (down previously from $20.00) on shares of OptimizeRx in a research report on Thursday, November 14th. B. Riley decreased their target price on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Royal Bank of Canada cut their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.19.

OptimizeRx Stock Up 2.3 %

Shares of OPRX opened at $4.94 on Tuesday. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $91.00 million, a PE ratio of -3.71 and a beta of 1.34. The business’s 50 day moving average is $5.28 and its 200 day moving average is $7.67.

Insiders Place Their Bets

In related news, CEO William J. Febbo purchased 20,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the transaction, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OPRX. BNP Paribas Financial Markets boosted its stake in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the period. Connors Investor Services Inc. lifted its stake in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the last quarter. Rhumbline Advisers boosted its position in shares of OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after buying an additional 2,658 shares during the period. Greenwood Capital Associates LLC grew its stake in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock valued at $520,000 after buying an additional 4,999 shares during the last quarter. Finally, Quest Partners LLC raised its holdings in shares of OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the period. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.